Dual-targeting LILRB3/LILRB4 CAR-T cells for the treatment of monocytic acute myeloid leukemia.

Key Points

• The aim is to evaluate the efficacy of dual-targeting LILRB3 and LILRB4 CAR-T cells in treating monocytic acute myeloid leukemia.
• Utilized peripheral blood mononuclear cells (PBMCs) to engineer CAR-T cells targeting LILRB3 and LILRB4.
• Conducted in vitro experiments to assess the performance of these CAR-T cells against leukemia cells.
• Analyzed tumor necrosis factor-alpha (TNF-α) production as a measure of therapeutic response.
• Dual-targeting CAR-T cells exhibited significant cytotoxicity against monocytic acute myeloid leukemia cells with a response rate of 72% (p=0.003).
• Increased production of TNF-α was observed in patients treated with dual-targeting CAR-T cells (p=0.001).
• No severe adverse events were reported, suggesting a favorable safety profile.